Insights

Gathering insights about Alto…

Similar companies to Alto

Alto Tech Stack

Alto uses 8 technology products and services including Site Kit, Cart Functionality, Google Fonts API, and more. Explore Alto's tech stack below.

Site Kit
Analytics
Cart Functionality
E-commerce
Google Fonts API
Font Scripts
OWL Carousel
Javascript Libraries
Auxilia
Payment Processing
HSTS
Security
Ninja Forms
Web Platform Extensions
Max Mega Menu
Widgets

Media & News

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the.
Feb 13, 2026 | www.businesswire.com
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donn.
Feb 03, 2026 | www.businesswire.com
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec.
Jan 14, 2026 | www.businesswire.com
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #ACNP--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company's development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. “We are pleased to have the opportunity to showcas.
Jan 13, 2026 | www.businesswire.com
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) were down 6% during mid-day trading on Friday. The company traded as low as $16.90 and last traded at $16.74. Approximately 59,931 shares changed hands during trading, a decline of 86% from the average daily volume of 425,848 shares. The stock had previously closed
Jan 04, 2026 | www.defenseworld.net
Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.
AWM Investment Company Inc. trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE: ANRO) by 68.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,483 shares of the company's stock after selling 621,501 shares during the
Dec 13, 2025 | www.defenseworld.net
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 150,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement Plan as a mate.
Dec 03, 2025 | www.businesswire.com

Alto's Email Address Formats

Alto uses at least 2 format(s):

Alto Email Formats	Example	Percentage
First@assai.tech	John@assai.tech	100%

Frequently Asked Questions

Where is Alto's headquarters located?

Alto's main headquarters is located at Jonesborough, Tennessee 37659 United States. The company has employees across 2 continents, including AsiaNorth America.

What is Alto's stock symbol?

Alto is a publicly traded company; the company's stock symbol is ANRO.

What is Alto's official website and social media links?

Alto's official website is altoweb.net and has social profiles on LinkedIn.

What is Alto's SIC code NAICS code?

Alto's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Alto have currently?

As of February 2026, Alto has approximately 4 employees across 2 continents, including AsiaNorth America. Key team members include Executive Director: D. D.. Explore Alto's employee directory with LeadIQ.

What industry does Alto belong to?

Alto operates in the Advertising Services industry.

What technology does Alto use?

Alto's tech stack includes Site KitCart FunctionalityGoogle Fonts APIOWL CarouselAuxiliaHSTSNinja FormsMax Mega Menu.

What is Alto's email format?

Alto's email format typically follows the pattern of First@assai.tech. Find more Alto email formats with LeadIQ.

When was Alto founded?

Alto was founded in 2011.

Alto

Q: What is Alto's official website and social media links?

Alto's official website is altoweb.net. Alto has social profiles on LinkedIn.

Q: How many employees does Alto have currently?

Alto has approximately 4 employees.

Q: What technology does Alto use?

Alto's tech stack includes X-Content-Type-Options, Web Vitals, Facebook, Google Analytics, HTTP/3.

Advertising ServicesTennessee, United States2-10 Employees

We provide services that will help grow your business. This includes web design and search engine optimization, online marketing, website maintenance, web hosting, and more. 
Our website design and development is about much more than just creating a nice looking website. We can help you grow your business and create leads with our thorough and complete approach to your business's online presence. Our websites rank extremely well in search engines and receive more traffic!

Company Overview

Headquarters: Jonesborough, Tennessee 37659 United States
Website: altoweb.net
SIC Code: 8742 - Management Consulting Services
Stock Symbol: ANRO
NAICS Code: 541613 - Marketing Consulting Services
Founded: 2011
Employees: 2-10

Media & News

Funding & Financials

$1M$10M
Alto's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Alto's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Alto

Duda

Strikingly

Squarespace

Jimdo

Weebly

Webflow

Alto Tech Stack

Media & News

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why

Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto's Email Address Formats

Frequently Asked Questions

Where is Alto's headquarters located?

What is Alto's stock symbol?

What is Alto's official website and social media links?

What is Alto's SIC code NAICS code?

How many employees does Alto have currently?

What industry does Alto belong to?

What technology does Alto use?

What is Alto's email format?

When was Alto founded?

Alto

Company Overview

Media & News

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?